Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinically meaningful improvements in erectile function at week 4, following a single 3-day oral treatment with LIB-01. Furthermore, the effect was sustained at week 8 and showed statistical significance in one of the pre-specified subgroups. Treatment with LIB-01 remained well tolerated. Based on the results, Dicot Pharma will now proceed with the development of LIB-01 according to plan with initiation of a phase 2b study during 2026.
Dicot Pharma’s phase 2a study (NCT06703840) aimed to investigate the efficacy and safety of the drug candidate LIB-01 for treatment of erectile dysfunction (ED). The double-blind, placebo-controlled study included 156 men, ages 26 to 65, with mild to moderate ED, classified as 11–25 on the regulatory and clinically relevant International Index of Erectile Function - Erectile Function domain score (IIEF-EF). The trial evaluated LIB-01 at three different doses, 10 mg, 25 mg, and 50 mg. Participants were assessed at four and eight weeks to evaluate the effect of LIB-01.
Please click here to read more